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PredictionA wealth of in vitro toxicological information on different types of tobaccos and tobacco products has
been acquired and published, although the link between in vitro data and impact on human health
remains elusive. The present study investigates the possibility of establishing quantitative models for
the in vitro toxicological endpoint responses to cigarette smoke. To this end, it relies on information sub-
mitted to Canadian health authorities during the period 2006–2012. To our knowledge, this is the ﬁrst
time that published results concerning the inﬂuence of such factors as cigarette blend, diameter and ﬁlter
type on in vitro toxicity are conﬁrmed at the level of a representative range of products on a market. Tak-
ing these cigarette design features into account and adding a limited amount of quantitative mainstream
smoke composition information, it is shown that, within the boundaries of the considered cigarette
design parameters, the in vitro toxicological response can be effectively predicted. In vitro tests of tobacco
products are an invaluable initial comparative product assessment tool. The present results reveal the
limited value of data from repeated tests on products which do not undergo signiﬁcant modiﬁcations.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
A wealth of information with regards to in vitro toxicity of dif-
ferent types of tobaccos and tobacco products has been generated
(National Cancer Institute, 1976; Paschke et al., 2002; Richter et al.,
2010; Thayer and Kensler, 1964). In fact, in vitro tests have been in-
cluded as a standard industry practice for product assessment
(Baker et al., 2004; Bombick et al., 1997; Carmines, 2002; Dempsey
et al., 2011; Doolittle et al., 1990; Roemer et al., 1998; Zenzen et al.,
2012), and regulatory authorities have also come to use them as
one of the sources of product information (Health Canada,
2005b). In vitro toxicity testing of tobacco products provides valu-
able information for the characterization of the relative toxicity of
different products, and different types of assays are chosen to
investigate the different types of cell and DNA responses to expo-
sure to tobacco smoke (CORESTA In Vitro Toxicology Task Force,
2004; Dempsey et al., 2011). Nevertheless, the relationship be-
tween in vitro toxicity and human smoking-related disease re-mains inconclusive (Brownawell, 2007; Byrd, 2004; Johnson
et al., 2009). Although relationships between certain in vitro and
in vivo endpoints have been discussed (Vanparys et al., 2012), it
is considered that even in vivo testing would not provide results
readily generalizable to evaluating the health effects in humans
(Klaassen and Eaton, 1991; SCHER/SCENIHR/SCCS, March 2013).
A number of factors have been identiﬁed as inﬂuencing the
in vitro toxicological activity of cigarette smoke. The inﬂuence of
tobacco type and blend (Tso, 1999) has been extensively studied
(Bombick et al., 1998; DeMarini et al., 2008; Richter et al., 2010;
Rickert et al., 2007; Roemer et al., 2009, 2004; Roeper et al.,
2004; Schramke et al., 2006; Yauk et al., 2012). Design features
such as cigarette diameter and presence of activated carbon in
the ﬁlter (Browne, 1990) have also been demonstrated to impact
certain in vitro endpoints (Coggins and Gaworski, 2008; Irwin,
1989). Even the stalk position of the tobacco leaf has emerged as
a possible inﬂuencing factor (Bombick et al., 1998). Filter ventila-
tion (Norman, 1999) has also been reported to impact in vitro tox-
icological endpoint response (Rickert et al., 2007), but is not
considered in the present study because all included in vitro data
were obtained under a smoking regimen which requires complete
blocking of ventilation holes.
Through the analysis of a single large data set collected in the
frame of regulatory submissions to Canadian authorities, the
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strated to have an impact on in vitro endpoints were evaluated.
In 2000, Canadian authorities introduced the Tobacco Reporting
Regulations (Health Canada, 2000). This federal law requires each
tobacco manufacturer and importer to annually provide Health
Canada with by-brand information on sales data, research activi-
ties, promotional activities, manufacturing information, product
ingredients, over 20 tobacco constituents and more than 40 prod-
uct emissions (smoke constituent yields). This information consti-
tutes a very detailed description of each cigarette brand, from basic
design features to end-performance.
In 2005, Canadian authorities extended the reporting require-
ments by introducing Regulations Amending the Tobacco Report-
ing Regulations (Health Canada, 2005b). These additionally
required three toxicity tests to be performed annually on each
brand. The three in vitro tests selected were the Ames bacterial
mutagenicity test (Health Canada, 2004a; Maron and Ames,
1983), the neutral red uptake (NRU) cytotoxicity test (Babich
and Borenfreund, 1992; Borenfreund and Puerner, 1985; Health
Canada, 2004b), and the micronucleus (MN) clastogenicity test
(Countryman and Heddle, 1976; Fenech, 2000; Health Canada,
2004c). Initially, the Canadian authorities introduced them as a
change control method, to monitor for possible unintended conse-
quences of the then-novel requirement of reduced cigarette igni-
tion propensity (RCIP) (Health Canada, 2005a) which affected all
cigarette brands on the market. The hypothesis that RCIP paper
could increase the toxicity of cigarettes has since been refuted
(e.g. (World Health Organization, 2008) and references therein),
but the annual in vitro toxicity data reporting requirement remains.
The subject of the indeﬁnite continuation of the requirement to
provide in vitro toxicity data as part of the yearly submission was
debated. In vitro tests are a valuable source of information to assess
the relative toxicity of novel products or novel product design fea-
tures (Dempsey et al., 2011). In a public consultation, tobacco
industry members suggested to the Canadian Department of
Health that ‘‘re-testing is not necessary if a product has not been mod-
iﬁed beyond conventional parameters . . .’’ (Health Canada, 2005a).
Nonetheless, the Canadian Department of Health concluded that
‘‘manufacturers often make changes to their cigarettes’’ (Health Can-
ada, 2005a) and maintained their requirement for annual toxicity
testing (Health Canada, 2005a,b).
The present study investigates whether annual in vitro toxico-
logical testing generates information which is not reﬂected in the
other content of the submissions to Health Canada, when product
changes are conﬁned to conventional adjustments. A conventional
adjustment is deﬁned here as a change of cigarette design fea-
tures and mainstream smoke deliveries (Appendix A) within
ranges typical of the investigated product set. For example, a cig-
arette change achieved by modifying the cigarette ﬁlter design or
paper while remaining within the ranges deﬁned by the other
products in the set is a conventional adjustment, whereas the ori-
ginal introduction of novel requirements such as RCIP (Health
Canada, 2005a) is not.
The investigation is conducted using data submitted by Roth-
mans, Benson & Hedges – the Canadian afﬁliate of Philip Morris
International – to Health Canada. The database includes information
submitted on 88 unique brands during the period 2006–2012. It is
demonstrated, in a proof-of-concept manner, that quantitative
models with substantial predictive power can be built to link the
in vitro data with the remainder of the content of the regulatory
submissions when product changes are conﬁned to conventional
adjustments. This mathematical proof does not establish any
causal relationship between toxicity and cigarette design features
or mainstream smoke constituent yields; correlation does not
equal causation. For example, cigarette smoke consists of more
than 5000 constituents the interrelationships of which would beimpossible to follow. Correlations observed at this level may be
indicative of very complex associations in the cigarette smoke
per se, and therefore cannot be assumed to be directly in the cau-
sation line.2. Materials and methods
2.1. Data set
All data included in the present study correspond to, or are di-
rectly derived from, data submitted to Canadian authorities in the
period 2006–2012. Data submitted in the period 2006–2011 are
used throughout the whole analysis, and are referred to as the pre-
diction set. Data submitted in 2012 only serve to validate the con-
clusions, and are referred to as the validation set.
2.1.1. Basic product information
Basic product information reported in accordance with year
2000 regulations (Health Canada, 2000) and considered in this
study is summarized in Appendix A: Cigarette attributes. It in-
cludes the submission year, some basic cigarette design features
and analytical data. Design features include the blend type (dark
air-cured, blended or Virginia ﬂue-cured), the ﬁlter type (regular
or activated carbon), and a cigarette diameter classiﬁcation (super-
slim or non-superslim, see Appendix A). The combination of these
three design features deﬁnes the cigarette type. The cigarette blend
type and the cigarette diameter classiﬁcations were derived from
the information in the submissions. One brand reported as dark
air-cured was classiﬁed as such in a group of one. Brands reported
as American Blend, or as containing all three of burley, Virginia
ﬂue-cured and oriental tobacco varieties, were classiﬁed as
blended. All remaining brands were reported as Virginia ﬂue-cured
and classiﬁed as Virginia ﬂue-cured. Cigarette brand variants with
a cigarette paper bobbin width (which is larger than the cigarette
circumference by the width of the seam) of 19 mm were classiﬁed
as superslim.
Analytical data include chemical analysis of the tobacco cut ﬁl-
ler and mainstream smoke (MS) constituent yields as determined
under the Health Canada Intense (HCI) smoking regime, which
speciﬁes a puff volume of 55 mL, a pufﬁng frequency of 2 puffs
per minute, a puff duration of 2 s and the requirement that ﬁlter
ventilation holes are blocked (Health Canada, 1999).
2.1.2. In vitro toxicity data
In vitro test results submitted in accordance with year 2005 reg-
ulations are referred to as in vitro data, and each individual assay
referred to as an endpoint. These endpoints are summarized in
Appendix B: In vitro endpoints. They include results on 10 end-
points from the Ames bacterial mutagenicity assay (5 bacterial
strains, each tested with and without S9 metabolic activation)
(Health Canada, 2004a; OECD, 1997); results on 3 endpoints from
the NRU cytotoxicity assay (exposures to the particulate phase
(PP), gas–vapor phase (GVP), and both combined (PP+GVP))
(Health Canada, 2004b); and results on 2 endpoints from the MN
assay (3-h exposure with and without S9 metabolic activation)
(Health Canada, 2004c). As per the regulatory requirements, all re-
sults are obtained solely with smoke fractions generated under HCI
smoking conditions (Health Canada, 2004a,b,c), which is also the
reason why only mainstream smoke constituent yields obtained
under HCI smoking conditions are considered for analysis among
the basic product information.
Regulatory submissions of in vitro data are required to indis-
criminately contain all the quantitative information obtained
and, as per regulatory requirements, no statistical treatment is per-
formed prior to data submission. However, not all in vitro assays
224 M. Belushkin et al. / Regulatory Toxicology and Pharmacology 68 (2014) 222–230are equally responsive to the cigarettes tested. For example, the
Ames bacterial mutagenicity assay is most frequently employed
to simply determine whether the test substance is mutagenic or
not, and the diversity of the possible effects is assessed using a
standard set of bacterial strains that are not necessarily expected
to all react positively. In its application to cigarette smoke conden-
sate, a quantitative comparison of mutagenicity values is sought;
in this case slopes of the number of revertant colonies per unit
mass TPM added to the bacterial culture are compared. For the
present data evaluation the test is considered non-responsive if
the slope of revertants per unit total particulate matter (TPM) dose
is not statistically different from zero (slope of linear region rule),
and if no TPM dose gives at least a twofold increase over the neg-
ative control (solvent) substance (twofold rule). Note that this
combination of the two requirements yields conservative conclu-
sions, and is selected because the twofold rule alone has limita-
tions (Kim and Margolin, 1999). Similarly, in the micronucleus
assay the relationship is considered non-responsive if the slope
of micronucleated cells per unit TPM dose is not statistically signif-
icantly different from zero. Conversely, no statistical test is per-
formed on the results from the NRU cytotoxicity assay. It is thus
always considered responsive in the present study.
2.1.3. Extent of the data set
The number of brands per year per cigarette type in the data set
is provided in Table 1 (Supplementary Material). Because the test-
ing was conducted by two laboratories, differentiation by labora-
tory facility is additionally made. HCI ‘tar’ values for the brands
range from 17 mg to 42 mg per cigarette, and the corresponding
ISO ‘tar’ values range from 0.7 mg to 15 mg per cigarette. ‘Tar’ is
calculated as the TPM yield minus the sum of the nicotine and
the water yields (International Organization for Standardization,
1991).
2.2. Data normalization
In vitro toxicological data are normalized to total particulate
matter (TPM) mass, a commonly used procedure to obtain
in vitro results from mainstream smoke exposure. Indeed, Ames
bacterial mutagenicity assay results are typically reported as the
number of revertants observed per unit mass of TPM added to
the bacterial plate (Roemer et al., 2004, 2009). The NRU cytotoxic-
ity assay results can be reported in terms of the inverse of the 50%
inhibitory concentration – mL per unit mass of TPM added to the
cell culture in the case of particle-phase exposure. When assaying
gas-phase components, the reporting convention is to relate the re-
sults to the mass of TPM collected alongside the tested GVP. The
micronucleus clastogenicity assay results are typically reported
as the number of micronucleated cells per unit mass of TPM added
to the cell culture.
In vitro data reported as above are an intensive rather than an
extensive property ranking the quality rather than the quantity
of the TPM. When relating the in vitro data to MS constituent
yields, the latter should also be normalized accordingly to ensure
comparability. Since the MS TPM values were unavailable in the
present study, the yield of each of the MS constituents was normal-
ized to ‘tar’ for the purpose of all the analyses. It is noted that due
to the high variability of water yield under HCI smoking conditions
(Purkis et al., 2011a), normalization to ‘tar’ may be expected to
provide more pertinent results for mechanistic investigations than
normalization to TPM.
2.3. Source laboratory selection
The data set contains in vitro results obtained in two different
laboratories: Labstat International ULC (Kitchener, Ontario,Canada) and Arista Laboratories (Richmond, Virginia, USA).
Although the methods used to perform the in vitro studies are
the same, inter-laboratory variability generates extra noise in addi-
tion to the inherent variability of the biological assays and the
methods (CORESTA In Vitro Toxicology Task Force, 2007; Oldham
et al., 2012). Thus although the analysis approach in the present
study could also be applied to data obtained in different laborato-
ries, this may reduce the robustness of results. Consequently,
because Labstat is the sole laboratory used since 2011 and contrib-
utes 87% of the total data (Table 1 in Supplementary Material), only
Labstat results are included in the analysis.3. Results and discussion
Three main questions are addressed in the present study. Which
in vitro endpoints are responsive to cigarette smoke? Do previously
reported relationships between selected cigarette design features
and in vitro response hold at the level of a broad range of products?
And can quantitative models speciﬁc to the considered product
range be built to predict the in vitro response?3.1. Assay response rates
The ﬁrst part of the study investigates which in vitro endpoints
yield meaningful data. The response rate of an assay can be deﬁned
as the percentage of responsive entries in the data set relative to
the total number of entries for that assay. The criteria for deﬁning
an entry non-responsive are discussed in Section 2.1.
As Fig. 1 demonstrates, the cytotoxicity assay is 100% respon-
sive by deﬁnition, and the micronucleus assay is highly responsive.
In the Ames assay, on the other hand, the situation is different.
Indeed, bacterial strains TA102 and TA1535 are essentially
non-responsive both with and without S9 metabolic activation.
Without metabolic activation, strain TA100 is non-responsive and
strain TA1537 is only responsive in about a quarter of all cases.
This is consistent with published results: most mutagens in TPM
of MS have been reported to require S9 metabolic activation, and
Ames endpoints without S9, even when responsive, have been
reported to yield signiﬁcantly lower responses than corresponding
endpoints with S9 (DeMarini, 1983; DeMarini et al., 2008; Rickert
et al., 2007).
In vitro endpoints with response rates at or below the few-per-
cent-level will not be considered further, thus the Ames TA100,
TA102, TA1535, TA102 +S9 and TA1535 +S9 endpoints are removed
from the analysis due to absence of data to facilitate further statis-
tical treatment (Fig. 1). The bacterial strain TA1537 without meta-
bolic activation (Ames TA1537 endpoint), which appears to
respond to mainstream smoke condensate in about a quarter of
all cases, exhibits a response which is random over all categories
of cigarette brand, blend type, ﬁlter type and cigarette diameter,
i.e. the pattern of non-zero responses is neither stable over time,
nor correlated with any of the aforementioned cigarette design
features. Therefore, the Ames TA1537 endpoint can be described
as consistently being on its ‘‘limit of detection’’ for all brands alike,
and therefore the data generated by this endpoint are best de-
scribed as analytical noise. It is therefore not considered in the
model.
Thus only 9 endpoints – Ames TA98, Ames TA98 +S9, Ames
TA100 +S9, Ames TA1537 +S9, NRU PP, NRU GVP, NRU PP+GVP,
MN and MN +S9, provide meaningful data. Summary statistics of
results obtained for these endpoints in each submission year are
provided in the Supplementary Material.
Fig. 1. Assay response rate deﬁned here as the percentage of responsive entries relative to the total in the data set. All Ames and micronucleus assays are performed on
particulate matter only. TA98, TA100, TA102, TA1535 and TA1537 are different Salmonella bacterial strains. +S9 refers to the presence of metabolic activation with the S9
enzyme fraction.
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The natural levels of variability of in vitro toxicity test results in
Labstat have recently been reported in the form of coefﬁcients of
variance (CV) calculated over a 30-month period for the assays per-
formed on a monitor cigarette (Wright and Rickert, 2007). These
numbers are broadly consistent with the average coefﬁcient of var-
iance (CV) per brand found in the present study calculated over the
period 2006–2011. The average CV per brand agrees within 1%
with the reported 30-month CV for the Ames TA98 +S9 and MN
+S9 endpoints, is lower by 5% for the Ames TA100 +S9 endpoint,
and does not exceed the reported 30-month CV by more than 7%
for the other endpoints.
Moreover, strong correlations exist between median values of
different cigarette types across the years. This conﬁrms that the an-
nual differences are attributable to the long-term variability of the
in vitro assays and methods, rather than changes in the products –
it is difﬁcult to imagine product changes affecting all brands in the
same way across different cigarette types across all years. For
example, the Pearson correlation coefﬁcient between the median
values of blended and Virginia ﬂue-cured cigarette types is statis-
tically signiﬁcant and exceeds 0.8 for the TA98 +S9, TA1537 +S9,
MN and MN +S9 endpoints, reaching a maximum value of 0.92
for the MN endpoint, and is at the level of 0.5–0.7 for the TA100
+S9, NRU PP, NRU GVP and NRU PP+GVP endpoints. Summary sta-
tistics for all endpoints are provided in Supplementary Material,
and summary statistics for the blended and Virginia ﬂue-cured cig-
arette types for three in vitro endpoints are additionally shown in
Fig. 2.
These results together suggest that the considered product
range has not undergone major changes, although it is noted that
in 2009, a ban on all cigarette ingredients with the exception of
processing aids such as humectants, was adopted in Canada
(Health Canada, 2010). As a result, in 2010 the blended brandsFig. 2. In vitro endpoint response in different years averaged over all blended brands (so
diameter) (dashed green). (For interpretation of the references to colour in this ﬁgure lewere reformulated, which normally results in a notable net reduc-
tion in the content of Burley and oriental tobacco varieties in the
blends. The main impact of this ban was on blended cigarettes be-
cause in these cigarettes tobacco additives are mainly used to re-
store sugar levels of air-cured tobaccos which lose essentially all
their sugar content during the curing process (Purkis et al.,
2011b; Roemer et al., 2012). It is noteworthy that this reformula-
tion does not appear to have impacted any of the in vitro endpoint
responses to the blended cigarettes (Fig. 2 and Supplementary
Material).
3.3. General relationships between in vitro data and cigarette design
features
A number of studies have explored the individual inﬂuence of
such cigarette design features as the blend type (Bombick et al.,
1998; DeMarini et al., 2008; Richter et al., 2010; Rickert et al.,
2007; Roemer et al., 2004, 2009; Roeper et al., 2004; Schramke
et al., 2006; Yauk et al., 2012), ﬁlter type (Coggins and Gaworski,
2008) and cigarette diameter (Irwin, 1989) on in vitro toxicity.
Here, they are conﬁrmed within a broad product range where dif-
ferent combinations of all the inﬂuencing factors are present at the
level of individual brands.
3.3.1. Discriminatory power of individual in vitro endpoints
Discriminatory power of a toxicological endpoint is deﬁned
here as that endpoint’s ability to distinguish between different cig-
arette types. Fig. 3 presents a comparison of the magnitudes of the
responses of each of the in vitro endpoints to the different cigarette
types, averaging over all brands of a given type and all prediction
years.
The Ames TA98 and MN +S9 endpoints both fail to differentiate
between the basic cigarette design features. This does not imply
that these two endpoints may not be useful in change control stud-lid red) and Virginia ﬂue-cured brands (non activated carbon ﬁlter, non-superslim
gend, the reader is referred to the web version of this article.)
Fig. 3. Discriminatory power of the different in vitro assays in terms of cigarette blend and design features. Bars show values averaged over all brands and years 2006–2011
for the designated cigarette type, and error bars show the corresponding standard errors. Differences which are statistically signiﬁcant in a t-test for differences are shown
with a ⁄(p < 0.05), ⁄⁄(p < 0.01) or ⁄⁄⁄(p < 0.001) symbol, respectively. ‘X’ denotes insufﬁcient data for statistical treatment. CF stands for ‘activated carbon ﬁlter’. SS stands for
‘superslim diameter’.
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tional (Dempsey et al., 2011). However, it is apparent that both
endpoints hardly distinguish between the different cigarette types,
and they are insensitive to any changes which may have been
made on the brands over the 6-year period considered.
The results for the other Ames endpoints are consistent with
published literature. The cigarette blend plays a major role in
determining the test result, and mutagenicity is higher for blended
cigarettes than for the Virginia ﬂue-cured blend cigarettes (Fig. 3,
left), in agreement with published data (Rickert et al., 2007; Roe-
mer et al., 2004). Indeed, Burley cigarette tobacco smoke is re-
ported to exhibit a higher mutagenicity than Virginia ﬂue-cured
tobacco smoke (Roeper et al., 2004; Schramke et al., 2006), with
blended cigarettes in between. The superslim cigarette diameter
also appears to have the expected (Irwin, 1989) reduction on the
Ames results (Fig. 3, right). There is no observable effect of acti-
vated carbon ﬁltration on the Ames bacterial mutagenicity results.
Indeed, activated carbon largely affects the gas–vapor phase of
smoke (Branton and Bradley, 2011; Gaworski et al., 2009), whereas
Ames assay studies are conducted with the particulate phase of
smoke.
The ability of the cytotoxicity assay to differentiate between dif-
ferent cigarette blends is also well-described in the literature. The
ranking compared to Ames mutagenicity is reversed, namely Vir-
ginia ﬂue-cured tobacco evokes a higher response in the NRU cyto-
toxicity assay than Burley tobacco (Bombick et al., 1998; Richter
et al., 2010; Rickert et al., 2007; Roemer et al., 2004, 2009; Roeper
et al., 2004). This is also reﬂected in the present study, whereby
Virginia ﬂue-cured cigarettes generally evoke a higher cytotoxicity
assay response than blended cigarettes (Fig. 3, right). Activated
carbon ﬁltration has an impact on the composition of the gas–va-
por phase, which affects results for activated carbon ﬁlter ciga-
rettes assayed for NRU GVP and NRU PP+GVP endpoints (Fig. 3),
consistent with previously reported results (Coggins and Gaworski,
2008).
The micronucleus assay has been reported to show very low by-
blend speciﬁcity (DeMarini et al., 2008; Yauk et al., 2012). This is
conﬁrmed in the present study (Fig. 3, right). Indeed, the MN +S9
endpoint is essentially constant both in time (see Supplementary
Material and Fig. 2) and across different cigarette types (Fig. 3,
right), and the MN endpoint is barely an improvement. Further-
more, both endpoints appear sensitive neither to the effects of acti-
vated carbon ﬁltration nor to cigarette diameter.3.3.2. Correlations between in vitro results and mainstream smoke
constituents
Authors have often pointed to strong correlations between cer-
tain smoke constituent classes and in vitro toxicity test results.In the Ames assay, strong correlations between the in vitro re-
sults and levels of nonvolatile polycyclic nitrogen compounds in
MS have been reported (DeMarini et al., 2008; Rickert et al.,
2007; Yauk et al., 2012). These correlations are conﬁrmed in the
present study for Ames endpoints with S9 metabolic activation:
the Pearson correlation coefﬁcient between the in vitro response
and levels of nitrogen oxides in mainstream smoke – a proxy for
other nitrogen-containing compounds (Piadé et al., 2013), is 0.83
for the TA98 +S9 endpoint, 0.51 for the TA100 +S9 endpoint, and
0.73 for the TA1537 +S9 endpoint. Additionally, a previously
reported negative correlation between mutagenicity in the Ames
assay and formaldehyde (Rickert et al., 2011) is conﬁrmed (Pearson
correlation coefﬁcients 0.75 for the TA98 +S9 endpoint, 0.53 for
the TA100 +S9 endpoint, and 0.63 for the TA1537 +S9 endpoint).
It can be attributed to reported negative correlations between the
yields of nitrogen-containing compounds and formaldehyde (Piadé
et al., 2013). These results are illustrated in Fig. 4.
In addition, the separation between non-superslim and super-
slim cigarettes in Ames results (Fig. 4) coincides with the reported
lower deliveries of aromatic amines from superslim cigarettes
compared to non-superslim cigarettes (Siu et al., 2013).
In the NRU cytotoxicity assay, a strong correlation between the
levels of acrolein and NRU GVP endpoint has been reported (Tewes
et al., 2003). However, the CV of acrolein (per mg ‘tar’) in the con-
sidered range of products is less than 10%, and consequently this
correlation cannot be easily conﬁrmed (Pearson correlation coefﬁ-
cient 0.14).3.4. Predictive power
The previously reported inﬂuence of cigarette blend, diameter
and ﬁlter type on the response of the considered toxicological end-
points has been conﬁrmed at the level of a representative product
range. Furthermore, a number of previously reported correlations
between in vitro toxicity endpoints and smoke constituent yields
are also conﬁrmed. The remaining question is whether this infor-
mation is sufﬁcient to construct a quantitative model which would
be capable of effectively predicting in vitro endpoint response. A
modeling approach was thus performed to investigate to what ex-
tent in vitro toxicity response can be explained quantitatively from
the remainder of the information present in the product informa-
tion submissions.
It should already be noted that the purpose of the present study
is not to provide quantitative models for all in vitro endpoints.
Rather, it is to investigate the possibility of constructing useful
models. In effect, the existence of a quantitative predictive model
would provide evidence that in vitro data do not add further
information on top of the other content of the mandatory submis-
Fig. 4. (Left) correlations between mutagenicity in the Ames assay and nitrogen-containing compounds can be visualized by studying one of the Ames endpoints in terms of
mainstream smoke yields of nitrogen oxides – a proxy for other nitrogen-containing compounds (Piadé et al., 2013). The clustering of dark air-cured, blended and Virginia
ﬂue-cured cigarettes (Rickert et al., 2007; Roemer et al., 2004; Roeper et al., 2004; Schramke et al., 2006) is conﬁrmed. (Right) apparent negative correlation between
formaldehyde and mutagenicity in the Ames assay reported previously (Rickert et al., 2011) can be explained by negative correlations between formaldehyde and nitrogen-
containing compounds (Dempsey et al., 2011; National Cancer Institute, 1976; Piadé et al., 2013). CF stands for ‘activated carbon ﬁlter’. SS stands for ‘superslim diameter’.
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the model.
3.4.1. Quantitative models: proof of concept
According to the estimate of the natural variability of the
biological assays and methods (Wright and Rickert, 2007) and
average brand CV as discussed in Section 3.2, a good model of
the data can be expected to explain up to 70–80% of the variance.
This can indeed be achieved. For example, an analysis of variance
(ANOVA) of the Ames TA98 +S9 endpoint shows that one factor,
namely cigarette type (one of dark air-cured, blended, Virginia
ﬂue-cured, Virginia ﬂue-cured activated carbon ﬁlter, Virginia
ﬂue-cured superslim diameter, Virginia ﬂue-cured activated car-
bon ﬁlter superslim diameter) accounts for about 60% of variance
in the data. Adding the MS yields of nitrogen oxides (NOx) and the
four aromatic amines (1-aminonaphthalene, 2-aminonaphthalene,
3-aminobiphenyl and 4-aminobiphenyl) as predictors to the lin-
ear model accounts for about 80% of the variance, precisely in line
with the expectations for a good model. A comparison of the val-
ues predicted from this linear model to the measured values is
shown in Fig. 5 (left). The predictive set of data – in vitro toxicity
results submitted in years 2006–2011, are the data on which the
linear model is built. The year 2012 data serve to validate the
model, as they are not included in the regression. To judge the
goodness-of-ﬁt of the model, R2 values are calculated. In the caseFig. 5. Linear model results comparing predicted and measured values in the Ames TA9
linear model includes cigarette type (blend type, diameter and ﬁlter type) and the MS y
includes cigarette type and the yields of three constituents which are representative of
Black squares show the year 2006–2011 data from which the linear model is built (predic
regression (validation set), and are thus a prediction. The limiting factor for modeling is t
colour in this ﬁgure legend, the reader is referred to the web version of this article.)of the Ames TA98 +S9 endpoint, R2 = 0.83 for the predictive set,
and the corresponding adjusted R2 that adjusts for the number
of model parameters versus the number of data points is
R2adj = 0.75. R
2 is 0.83 also for the validation set (Fig. 5, left), con-
ﬁrming that the variance unaccounted for is comparable to the
expected natural variability.
The situation is different for in vitro endpoints where the assay
and method variability is close to the total CV of all products, i.e.
when the total variability of the response across all the different
brands is comparable to the expected natural variability. This is,
for example, the case for the NRU PP+GVP endpoint. A model of
these data can be constructed by means of a mathematically-
driven approach (see e.g. Seilkop et al., 2012) using different com-
binations of MS constituent yields representative of particle- and
gas-phase compounds. For example, a model using the cigarette
type and the MS yields of phenol, CO and 4-aminobiphenyl does
capture the inherent trends, but the variability of the assay is larger
than the observed effect. The results of this model are presented in
Fig. 5, right. In this case, the adjusted R2 value is only 0.3. It is
stressed that these smoke constituents are chosen solely for their
strong mathematical correlation with the NRU PP+GVP endpoint
data, and that other combinations of smoke constituents can
provide similar results.
Quantitative models for the other endpoints can be constructed
in a similar fashion. As detailed above for the two extreme cases,8 +S9 toxicity endpoint (left) and NRU PP+GVP toxicity endpoint (right). The Ames
ields of nitrogen oxides (NOx) and the four aromatic amines. The NRU linear model
gas-phase and particle-phase constituent yields: phenol, CO and 4-aminobiphenyl.
tive set). Magenta squares show the year 2012 data which were not included in the
he 20%-level relative variability of the assays. (For interpretation of the references to
228 M. Belushkin et al. / Regulatory Toxicology and Pharmacology 68 (2014) 222–230the corresponding goodness-of-ﬁt measures depend mainly on the
magnitude of the overall variance of the corresponding in vitro
endpoint.
In principle, such modeling makes quantitative predictions for
each in vitro toxicity endpoint, and the typical error estimate is a
direct consequence of the variance of the assay and method, at a
level of about 20%. However, the model relies on correlations
which should not be confused with causation. Speciﬁcally, the
MS constituents selected for the models described above are not
necessarily linked to any of the in vitro endpoints in a cause-and-
effect manner. For example, the model for the TA98 +S9 endpoint
is ‘‘response = Const + 0.004⁄NOx + 0.117⁄1AN + 0.166⁄2AN + 7.450⁄3-
AB  3.037⁄4AB’’, where NOx, 1AN, 2AN, 3AB and 4AB stand for
tar-normalized yields of nitrogen oxides, 1-aminonaphthalene, 2-
aminonaphthalene, 3-aminobiphenyl and 4-aminobiphenyl ex-
pressed in lg/mg tar (NOx) and ng/mg tar (aromatic amines),
respectively, and the type-speciﬁc constant ‘‘Const’’ is 0.203469
for blended, 0.085512 for dark air-cured, 0.133976 for Virginia
ﬂue-cured, 0.119047 for Virginia ﬂue-cured activated carbon ﬁlter,
0.012423 for Virginia ﬂue-cured activated carbon ﬁlter superslim,
and 0.076298 for Virginia ﬂue-cured superslim cigarettes. The
units of the model parameters are such that the resulting response
has the units of revertants/lg TPM. However, it has been shown
that the actual contribution to the overall mutagenicity of a broad
set of compounds that includes those appearing in the equation
above is smaller than 0.1% (Tewes et al., 2003). For the purpose
of the present study, many other combinations of smoke constitu-
ents, none of which would be necessarily linked to mutagenicity in
a cause-and-effect manner, could have been used to achieve com-
parable predictive power. Conversely, not all compounds which are
known to cause a signiﬁcant portion of the magnitude of the re-
sponse of a given end-point are useful predictors. For example,
acrolein which is known to contribute over 40% to the cytotoxicity
of the gas–vapor phase (Tewes et al., 2003) is not a useful predictor
of this endpoint in the present study. This is likely because the CV
of acrolein yields (per mg ‘tar’) across all brands is very small, un-
der 10%. A likely reason for this is the fact that the smoke data are
obtained under the HCI smoking regime, whereby adsorbance ef-
fects in the cigarette ﬁlter are limited (Purkis et al., 2010a,b).
Fundamentally, the use of the model is restricted to the range of
parameters on which it has been established.4. Conclusions
Data for 15 in vitro toxicological endpoints mandated for report-
ing by Canadian regulatory authorities was considered in the pres-
ent study for a representative product range comprised of 88
unique brands, over a 7-year period. It was demonstrated that only
7 of these in vitro endpoints (Ames TA98 +S9, Ames TA100 +S9,
Ames TA1537 +S9, NRU PP, NRU GVP, NRU PP+GVP and MN) pro-
vide data which differentiates between some fundamental ciga-
rette design features. It was further shown that in the absence of
meaningful product changes, the response can be predicted up to
the level of natural variability of the biological assays and methods.
In vitro toxicological studies are useful for the assessment of no-
vel products or product modiﬁcations (Dempsey et al., 2011), but
the 7 years of in vitro toxicity data investigated in the present study
do not provide additional information further to that contained in
submissions according to the original Health Canada requirements
(Health Canada, 2000) because the products had been subjected
only to conventional adjustments. The introduction of novel prod-
uct design features would readily be reﬂected in the submissions
according to the original Health Canada requirements.
It should be noted that the response in in vitro toxicity assays, in
particular in vitro data for cigarette smoke, is generally not consid-ered to be directly predictive of health outcome (Johnson et al.,
2009), and thus also predictions of in vitro toxicological data can-
not be related directly to predictions of health outcome. Consistent
with the literature, in the present analysis there are differences in
the response of blended (higher in Ames bacterial mutagenicity
test) or Virginia ﬂue-cured (higher in NRU cytotoxicity test)
products in different in vitro assays, but this does not appear to
be the case for health outcome at the population level. Epidemio-
logical studies in predominantly Virginia ﬂue-cured or predomi-
nantly blended cigarette markets have shown that the cigarette
type does not appear to inﬂuence the risk of lung cancer or chronic
obstructive pulmonary disease (Lee et al., 2009).
In summary, the present study demonstrates that when no no-
vel design features are introduced within a range of cigarette prod-
ucts, e.g. when changes are limited to cigarette blend, ﬁlter design
or cigarette format, in vitro toxicity re-testing does not provide any
knowledge in addition to that contained already in the content of
submissions to Health Canada (Health Health Canada, 2000).
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Appendix A. Cigarette attributes











Filter type Regular or
activated
carbonCut ﬁller constituents (per gram of tobacco)
Nicotine lg/g Arsenic ng/g
Nornicotine lg/g Selenium ng/g
Anabasine lg/g Mercury ng/g
Myosmine lg/g Nitrate mg/g
Anatabine lg/g NNN ng/g
Ammonia lg/g NAT ng/g
Propylene glycol mg/g NAB ng/g





lg/gCadmium ng/g Triacetin lg/g
Chromium ng/g Sorbic acid lg/g
Nickel ng/g Benzo[a]pyrene ng/g
Lead ng/gMainstream smoke constituents (Health Canada Intense smoking
regime, per mg ‘tar’)Tar mg 1-
aminonaphthaleneng/mgNicotine mg/mg 2-
aminonaphthaleneng/mgCO mg/mg 3-aminobiphenyl ng/mg
Formaldehyde lg/mg 4-aminobiphenyl ng/mg
Acetaldehyde lg/mg Ammonia lg/mg
M. Belushkin et al. / Regulatory Toxicology and Pharmacology 68 (2014) 222–230 229Acetone lg/mg 1,3-Butadiene lg/mg
Acrolein lg/mg Isoprene lg/mg
Propionaldehyde lg/mg Acrylonitrile lg/mg
Crotonaldehyde lg/mg Benzene lg/mg
Methyl ethyl
ketone
lg/mg Toluene lg/mgButylaldehyde lg/mg Pyridine lg/mg
Hydroquinone lg/mg Quinoline lg/mg
Resorcinol lg/mg Styrene lg/mg
Catechol lg/mg NNN ng/mg
Phenol lg/mg NAT ng/mg
m,p-cresols lg/mg NAB ng/mg
o-cresol lg/mg NNK ng/mg
Benzo[a]pyrene ng/mg Mercury ng/mg
NO lg/mg Cadmium ng/mg
NOx lg/mg Lead ng/mg
HCN lg/mgCO – carbon monoxide; NO – nitrogen oxide; NOx – nitrogen oxides; HCN –
hydrogen cyanide; NNN – N0-nitrosonornicotine; NNK – 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone; NAT – N0-nitrosoanatabine; NAB – N0-nitrosoanabasine.
a Brands with a cigarette paper bobbin width of 19 mmwere classiﬁed superslim.
b One brand reported as dark air-cured was classiﬁed dark air-cured. Brands
reported as American Blend, or containing all three of Burley, oriental and Virginia
ﬂue-cured tobacco varieties were classiﬁed as blended. All other brands were
reported as Virginia ﬂue-cured and thus classiﬁed as Virginia ﬂue-cured.Appendix B. In vitro endpoints






activationTA98 No (Ames TA98) TA98 Yes (Ames TA98
+S9)TA100 No (Ames
TA100)TA100 Yes (Ames
TA100 +S9)TA102 No (Ames
TA102)TA102 Yes (Ames
TA102 +S9)TA1535 No (Ames
TA1535)TA1535 Yes (Ames
TA1535 +S9)TA1537 No (Ames
TA1537)TA1537 Yes (Ames
TA1537 +S9)Neutral red uptake cytotoxicity assay (NRU): smoke fraction
Particulate phase (NRU PP)
Gas–vapour phase (NRU GVP)
Particulate and gas–vapour phase (NRU PP+GVP)
Micronucleus assay (MN)
Without S9 metabolic activation (MN)
With S9 metabolic activation (MN +S9)
In principle, a requirement exists to report an additional endpoint in the micro-
nucleus clastogenicity assay, namely 30-h exposure without S9 metabolic activa-
tion (Health Canada, 2004c). This endpoint is not included in the present analysis
due to absence of data, since according to regulations it would only need to be
reported if the 3-h period of treatment, both with and without S9 metabolic acti-
vation, would yield ‘‘negative or equivocal results’’ (Health Canada, 2004c).Appendix C. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.yrtph.2013.
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